Emmaus Life Sciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

STOCKHOLDERS' DEFICIT (Details Narrative)

STOCKHOLDERS' DEFICIT (Details Narrative) - USD ($)			1 Months Ended		6 Months Ended	12 Months Ended
STOCKHOLDERS' DEFICIT (Details Narrative) - USD ($)	Feb. 26, 2021	Jun. 15, 2020	Sep. 30, 2022	Jun. 30, 2022	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Jun. 15, 2022	Sep. 29, 2021	Feb. 09, 2021	Dec. 31, 2020	Dec. 31, 2018	Oct. 31, 2018
Class Of Warrant Or Right [Line Items]
Convertible notes principal amount						$ 27,562,000	$ 18,007,000
Percentage of monthly payments interest rate													1.00%
Loss on debt extinguishment						$ 501,000	$ 365,000
Common stock, issued						49,583,501	49,311,864
Warrant derivative liabilities						$ 70,000	$ 1,503,000
Change in fair value of warrant derivative liabilities						$ 1,304,000	(432,000)
Average remaining contractual terms for warrants						2 years 1 month 6 days
Share-based compensation						$ 16,000	553,000
Research and development						1,725,000	4,110,000
Adjustment of warrants change in fair value increase additional paid in capital and accumulated loss					$ 446,000
Common stock issued for services						$ 119,000	$ 500,000
Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Common stock issued for services (in shares)						271,637	324,675
Common stock issued for services						$ 1,000
Stock Options [Member]
Class Of Warrant Or Right [Line Items]
Period remaining for recognition of unrecognized compensation cost						6 months
2011 Stock Incentive Option Plan [Member]
Class Of Warrant Or Right [Line Items]
Total unrecognized compensation cost						$ 5,000
2011 Stock Incentive Option Plan [Member] \| Stock Options [Member]
Class Of Warrant Or Right [Line Items]
Number of shares authorized under the plan												9,000,000
Expiration period						10 years
Vesting period						3 years
Share-based compensation						$ 16,000	$ 553,000
2021 Stock Incentive Option Plan [Member]
Class Of Warrant Or Right [Line Items]
Common stock, issued									4,000,000
Kainos Medicine, Inc [Member]
Class Of Warrant Or Right [Line Items]
Payments to research and development expense	$ 500,000
Common stock shares issued for consideration	324,675
Addition to equity for common stock	$ 500,000
Research and development						$ 0	$ 1,500,000
Amended and Restated Warrants [Member]
Class Of Warrant Or Right [Line Items]
Debt instrument exercise price				$ 0.446	$ 0.446
Number of common stock to be purchased						4,038,200
Professional Relations and Consulting Service [Member] \| Restricted Stock [Member] \| Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Common stock issued for services (in shares)				246,637		25,000
Common stock issued for services				$ 110,000		$ 9,000
Dr. Yutaka Niihara [Member]
Class Of Warrant Or Right [Line Items]
Warrants granted to purchase common stock			500,000
Debt instrument exercise price			$ 2.50
Warrants granted, term			5 years
Warrant derivative liabilities						70,000
Change in fair value of warrant derivative liabilities						$ 14,000
Convertible Promissory Note [Member]
Class Of Warrant Or Right [Line Items]
Number outstanding							1,250,000	1,250,000
Convertible Promissory Note [Member] \| Securities Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Convertible notes principal amount		$ 3,150,000
Debt instrument exercise price		$ 2.05
Percentage of monthly payments interest rate		12.00%								2.00%	11.00%
Extended maturity date		Jun. 15, 2023
Number outstanding		1,250,000
Loss on debt extinguishment		$ 1,400,000
Repayment of debt		$ 0
Expected life (in years)		5 years